We are live on ! Find out more
VCM

Voleon Capital Management Portfolio holdings

AUM $5.49B
1-Year Est. Return 56.94%
This Fund
S&P 500
This Quarter Est. Return
+31.2%
1 Year Est. Return
+56.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.49B
AUM Growth
+$849M
Cap. Flow
+$57M
Cap. Flow %
1.04%
Top 10 Hldgs %
29.1%
Holding
957
New
177
Increased
251
Reduced
333
Closed
196

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$41.7M
2
META icon
Meta Platforms (Facebook)
META
+$41.2M
3
MRK icon
Merck
MRK
+$26.1M
4
INTU icon
Intuit
INTU
+$24.7M
5
AZN icon
AstraZeneca
AZN
+$23.6M

Top Sells

Rank Stock Value
1
ALAB icon
Astera Labs
ALAB
+$29.3M
2
QCOM icon
Qualcomm
QCOM
+$28.6M
3
FTNT icon
Fortinet
FTNT
+$26.2M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$22.1M
5
LLY icon
Eli Lilly
LLY
+$20.8M

Sector Composition

Rank Sector Weight
1 Technology 34.25%
2 Financials 12.04%
3 Healthcare 11.39%
4 Industrials 10.72%
5 Consumer Discretionary 10.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LZ icon
751
LegalZoom.com
LZ
$1.04B
$82.1K ﹤0.01%
13,401
-36,168
-73% -$222K
RXRX icon
752
Recursion Pharmaceuticals
RXRX
$1.72B
$80.4K ﹤0.01%
21,894
-65,954
-75% -$220K
EGHT icon
753
8x8 Inc
EGHT
$266M
$77.2K ﹤0.01%
45,175
-19,724
-30% -$39.7K
WEAV icon
754
Weave Communications
WEAV
$585M
$69.3K ﹤0.01%
+11,561
New +$63K
ACHR icon
755
Archer Aviation
ACHR
$4.3B
$65.9K ﹤0.01%
+13,931
New +$81K
MRLN
756
Merlin Inc
MRLN
$301M
$63.9K ﹤0.01%
+11,222
New +$95K
ALT icon
757
Altimmune
ALT
$636M
$63K ﹤0.01%
20,715
-6,427
-24% -$19.2K
NRGV icon
758
Energy Vault
NRGV
$784M
$62.2K ﹤0.01%
+13,196
New +$59K
LCTX icon
759
Lineage Cell Therapeutics
LCTX
$255M
$60.9K ﹤0.01%
46,478
-39,261
-46% -$54.3K
SMRT icon
760
SmartRent
SMRT
$222M
$53K ﹤0.01%
+44,527
New +$56.5K
PALI icon
761
Palisade Bio
PALI
$359M
$39.4K ﹤0.01%
+18,847
New +$37.1K
ACDC icon
762
ProFrac Holding
ACDC
$949M
– –
-21,689
Closed -$134K
ACLX
763
DELISTED
Arcellx
ACLX
– –
-56,720
Closed -$6.51M
ADCT icon
764
ADC Therapeutics
ADCT
$137M
– –
-513,831
Closed -$1.93M
ADMA icon
765
ADMA Biologics
ADMA
$2.07B
– –
-23,366
Closed -$211K
AEP icon
766
American Electric Power
AEP
$67.1B
– –
-2,348
Closed -$308K
AFL icon
767
Aflac
AFL
$57.8B
– –
-1,867
Closed -$205K
AGIO icon
768
Agios Pharmaceuticals
AGIO
$2.01B
– –
-9,679
Closed -$327K
AJG icon
769
Arthur J. Gallagher & Co
AJG
$61.6B
– –
-925
Closed -$200K
AKBA icon
770
Akebia Therapeutics
AKBA
$264M
– –
-675,656
Closed -$939K
ALB icon
771
Albemarle
ALB
$13.9B
– –
-17,359
Closed -$3.12M
AON icon
772
Aon
AON
$64.2B
– –
-10,159
Closed -$3.28M
APP icon
773
Applovin
APP
$108B
– –
-10,933
Closed -$4.35M
ARIS
774
Aris Mining
ARIS
$4.03B
– –
-43,346
Closed -$805K
ARVN icon
775
Arvinas
ARVN
$553M
– –
-75,537
Closed -$801K
29 30
31
32 33

Similar funds

GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
GCM
Graham Capital Management Rowayton, Connecticut $5.5B AUM 26.66% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
MC
Maplelane Capital New York $5.51B AUM 67.92% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Voleon Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Voleon Capital Management held 957 positions worth $5.49B, up 18% from $4.64B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Voleon Capital Management's Q2 2026 filing shows 177 new, 251 increased, 333 reduced and 196 closed positions. Its largest new stake was AstraZeneca: 125,385 shares worth $23.8M. The largest sale was Astera Labs, an estimated $29.3M.

By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 29% a quarter earlier, followed by Financials and Healthcare.

  • Voleon Capital Management's largest Q2 2026 buy was AstraZeneca: 125,385 shares worth $23.8M.
  • Voleon Capital Management added most to Microsoft in Q2 2026, an estimated $41.7M increase.
  • Voleon Capital Management's biggest Q2 2026 reduction was Astera Labs, cutting an estimated $29.3M.
  • Voleon Capital Management fully exited Ascendis Pharma A/S in Q2 2026, selling an estimated $15.5M.
  • Voleon Capital Management's ten largest holdings make up 29% of its $5.49B portfolio in Q2 2026.
  • Voleon Capital Management opened 177 new positions and closed 196 in Q2 2026.
  • Voleon Capital Management's portfolio value rose 18% quarter-over-quarter to $5.49B.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.